Alzheimer’s Disease – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Alzheimer’s Disease – Pipeline Review, H2 2019’, provides an overview of the Alzheimer’s Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Alzheimer’s Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer’s Disease and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Alzheimer’s Disease

– The report reviews pipeline therapeutics for Alzheimer’s Disease by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Alzheimer’s Disease therapeutics and enlists all their major and minor projects

– The report assesses Alzheimer’s Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Alzheimer’s Disease”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“1st Bio Therapeutics Inc

2A Pharma AB

4D Pharma Plc

4P-Pharma SAS

AB Science SA

Abaxy Sprl

AbbVie Inc

AC Immune SA

Acelerox LLC

Acelot Inc

Actinogen Medical Ltd

Acumen Pharmaceuticals Inc

AcuraStem Inc

Addex Therapeutics Ltd

ADRx Inc

Aerobyx LLC

AfaSci Inc

Affichem SA

AFFiRiS AG

Aibios Co Ltd

Alector Inc

AlfaSigma SpA

Alion Pharmaceuticals Inc

Alkahest Inc

Alkermes Plc

Allgenesis Biotherapeutics Inc

ALS Biopharma LLC

Alsonex Pty Ltd

ALSP Inc

Alzamend Neuro Inc

AlzeCure Pharma AB

Alzheon Inc

Alzhyme Pty Ltd

Alzinova AB

AlzProtect SAS

Alzyn LLC

Amarantus Bioscience Holdings Inc

Amylon LLC

Amylyx Pharmaceutical Corp

Anavex Life Sciences Corp

Ankar Pharma SL

Annovis Bio Inc

Antoxerene Inc

Anven AlzDx Inc

Aphios Corp

Apodemus AB

Apollo Therapeutics LLC

Applied Research using OMIC Sciences SL

Aprinoia Therapeutics Inc

AptaBio Therapeutics Inc”

Table of Contents

Table of Contents

Table of Contents

Introduction

Alzheimer's Disease Overview

Alzheimer's Disease Therapeutics Development

Alzheimer's Disease Therapeutics Assessment

Alzheimer's Disease Companies Involved in Therapeutics Development

Alzheimer's Disease Drug Profiles

Alzheimer's Disease Dormant Projects

Alzheimer's Disease Discontinued Products

Alzheimer's Disease Product Development Milestones

Appendix

List of Tables

“List of Tables

Number of Products under Development for Alzheimer’s Disease, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Alzheimer’s Disease – Pipeline by 1st Bio Therapeutics Inc, H2 2019

Alzheimer’s Disease – Pipeline by 2A Pharma AB, H2 2019

Alzheimer’s Disease – Pipeline by 4D Pharma Plc, H2 2019

Alzheimer’s Disease – Pipeline by 4P-Pharma SAS, H2 2019

Alzheimer’s Disease – Pipeline by AB Science SA, H2 2019

Alzheimer’s Disease – Pipeline by Abaxy Sprl, H2 2019

Alzheimer’s Disease – Pipeline by AbbVie Inc, H2 2019

Alzheimer’s Disease – Pipeline by AC Immune SA, H2 2019

Alzheimer’s Disease – Pipeline by Acelerox LLC, H2 2019

Alzheimer’s Disease – Pipeline by Acelot Inc, H2 2019

Alzheimer’s Disease – Pipeline by Actinogen Medical Ltd, H2 2019

Alzheimer’s Disease – Pipeline by Acumen Pharmaceuticals Inc, H2 2019

Alzheimer’s Disease – Pipeline by AcuraStem Inc, H2 2019

Alzheimer’s Disease – Pipeline by Addex Therapeutics Ltd, H2 2019

Alzheimer’s Disease – Pipeline by ADRx Inc, H2 2019

Alzheimer’s Disease – Pipeline by Aerobyx LLC, H2 2019

Alzheimer’s Disease – Pipeline by AfaSci Inc, H2 2019

Alzheimer’s Disease – Pipeline by Affichem SA, H2 2019

Alzheimer’s Disease – Pipeline by AFFiRiS AG, H2 2019

Alzheimer’s Disease – Pipeline by Aibios Co Ltd, H2 2019

Alzheimer’s Disease – Pipeline by Alector Inc, H2 2019

Alzheimer’s Disease – Pipeline by AlfaSigma SpA, H2 2019

Alzheimer’s Disease – Pipeline by Alion Pharmaceuticals Inc, H2 2019

Alzheimer’s Disease – Pipeline by Alkahest Inc, H2 2019

Alzheimer’s Disease – Pipeline by Alkermes Plc, H2 2019

Alzheimer’s Disease – Pipeline by Allgenesis Biotherapeutics Inc, H2 2019

Alzheimer’s Disease – Pipeline by ALS Biopharma LLC, H2 2019

Alzheimer’s Disease – Pipeline by Alsonex Pty Ltd, H2 2019

Alzheimer’s Disease – Pipeline by ALSP Inc, H2 2019

Alzheimer’s Disease – Pipeline by Alzamend Neuro Inc, H2 2019

Alzheimer’s Disease – Pipeline by AlzeCure Pharma AB, H2 2019

Alzheimer’s Disease – Pipeline by Alzheon Inc, H2 2019

Alzheimer’s Disease – Pipeline by Alzhyme Pty Ltd, H2 2019

Alzheimer’s Disease – Pipeline by Alzinova AB, H2 2019

Alzheimer’s Disease – Pipeline by AlzProtect SAS, H2 2019

Alzheimer’s Disease – Pipeline by Alzyn LLC, H2 2019

Alzheimer’s Disease – Pipeline by Amarantus Bioscience Holdings Inc, H2 2019

Alzheimer’s Disease – Pipeline by Amylon LLC, H2 2019

Alzheimer’s Disease – Pipeline by Amylyx Pharmaceutical Corp, H2 2019

Alzheimer’s Disease – Pipeline by Anavex Life Sciences Corp, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Alzheimer’s Disease, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports